RecruitingNCT05246345
Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia
Sponsor
University Hospital, Clermont-Ferrand
Enrollment
50 participants
Start Date
Mar 7, 2022
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this study is to collect medical informations and samples from refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax treatment, in order to evaluate the frequency of resistance mechanisms.
Eligibility
Min Age: 18 Years
Inclusion Criteria7
- Age greater than or equal to 18 years old;
- chronic lymphocytic leukemia diagnosis according to iwCLL criteria;
- refractory and/or relapsed disease during or after venetoclax treatment;
- tumor samples available.
- Relapse might be progressive chronic lymphocytic leukemia or transformation into Richter syndrome.
- Patients must be able to express their opposition to be enrolled in this study, if need be.
- Patients must be affiliated at the French Social Security system
Exclusion Criteria2
- Patients of their legal guardians refusing to participate
- \-
Locations(14)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05246345
Related Trials
Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
NCT070619511 location
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
NCT04269902627 locations
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
NCT06846671112 locations
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
NCT06943872155 locations
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
NCT0727723114 locations